Topics

Looking to Level Up in NASH, Novo Nordisk Licenses Ube Drug Candidate

20:08 EST 8 Nov 2019 | Xconomy

Danish diabetes giant Novo Nordisk took another step this week in its efforts to establish a presence in nonalcoholic steatohepatitis, or NASH, a metabolic disorder closely related to diabetes that is anticipated to become the leading cause of liver transplants in the US in coming years. The company Thursday announced it had inked a deal […]

Original Article: Looking to Level Up in NASH, Novo Nordisk Licenses Ube Drug Candidate

NEXT ARTICLE

More From BioPortfolio on "Looking to Level Up in NASH, Novo Nordisk Licenses Ube Drug Candidate"

Quick Search

Relevant Topic

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...